Scholarlink

Background <p>The global rise in obesity is predominantly driven by energy dense foods consumption and sedentary lifestyles that contribute to a growing burden of metabolic and neuroinflammatory comorbidities. Obesity is linked to a chronic low-grade inflammatory profile, as well as to a localized neuroendocrine imbalance and inflammatory response in the brain, including regions regulating energy homeostasis, reward and motivational centers. Anti-obesity medications that reduce body weight are being extensively used across the world, and the specific cerebral mechanisms underlying its action are yet to be clarified.</p> Methods <p>We investigated the cerebral and systemic effects inherent to obesity development and treatment with celastrol, an anti-obesity and anti-inflammatory agent, in a murine model of diet-induced obesity (DIO) using a multimodal approach. We characterized obesity progression and celastrol acute treatment by comparing body weight (BW), food intake, changes in brain microstructure by in vivo magnetic resonance imaging (MRI) and ex vivo by immunofluorescence (IF), investigated its metabolic rearrangements using <sup>1</sup>H high-resolution magic angle spinning spectroscopy and draw the hormonal profiles between DIO and control animals, with or without treatment.</p> Results <p>Our findings indicate that obesity induces detectable neuroinflammation, evident through diffusion MRI alterations and increased glial activation, with quantifiable morphological changes. Treatment resulted in significant BW reduction, diffusion MRI signal changes, particularly in the hypothalamus, a decrease in glial activation, a regularization of cerebral osmolyte concentrations, decreased cellular proliferation and astrocytic metabolism markers, and anti-inflammatory cytokine changes.</p> Conclusions <p>These results support the role of celastrol as an anti-obesity treatment, with anti-inflammatory effects in the hypothalamus and associated cerebral metabolic rearrangements, and prove MRI techniques as valid tools to characterize its effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acute anti-obesity treatment with celastrol reduces body weight, cerebral inflammation and metabolic imbalances in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Adriana Ferreiro,
  • Maya Holgado,
  • Raquel González-Alday,
  • Sara González-Soto,
  • Lidia M. Fernandez-Sevilla,
  • Ángeles Vicente,
  • Pilar López-Larrubia,
  • Blanca Lizarbe

摘要

Background

The global rise in obesity is predominantly driven by energy dense foods consumption and sedentary lifestyles that contribute to a growing burden of metabolic and neuroinflammatory comorbidities. Obesity is linked to a chronic low-grade inflammatory profile, as well as to a localized neuroendocrine imbalance and inflammatory response in the brain, including regions regulating energy homeostasis, reward and motivational centers. Anti-obesity medications that reduce body weight are being extensively used across the world, and the specific cerebral mechanisms underlying its action are yet to be clarified.

Methods

We investigated the cerebral and systemic effects inherent to obesity development and treatment with celastrol, an anti-obesity and anti-inflammatory agent, in a murine model of diet-induced obesity (DIO) using a multimodal approach. We characterized obesity progression and celastrol acute treatment by comparing body weight (BW), food intake, changes in brain microstructure by in vivo magnetic resonance imaging (MRI) and ex vivo by immunofluorescence (IF), investigated its metabolic rearrangements using 1H high-resolution magic angle spinning spectroscopy and draw the hormonal profiles between DIO and control animals, with or without treatment.

Results

Our findings indicate that obesity induces detectable neuroinflammation, evident through diffusion MRI alterations and increased glial activation, with quantifiable morphological changes. Treatment resulted in significant BW reduction, diffusion MRI signal changes, particularly in the hypothalamus, a decrease in glial activation, a regularization of cerebral osmolyte concentrations, decreased cellular proliferation and astrocytic metabolism markers, and anti-inflammatory cytokine changes.

Conclusions

These results support the role of celastrol as an anti-obesity treatment, with anti-inflammatory effects in the hypothalamus and associated cerebral metabolic rearrangements, and prove MRI techniques as valid tools to characterize its effects.